SARC-F Is a Predictor of Longer LOS and Hospital Readmission in Hospitalized Patients after a Cardiovascular Event

Fayh, Ana Paula Trussardi; Guedes, Francisco Felipe de Oliveira; Calado, Guilherme Carlos Filgueira; Queiroz, Sandra Azevedo; Anselmo, Marina Gabriely Gomes Barbosa; Sousa, Iasmin Matias de

doi:10.3390/nu14153154

Cited by 9 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Mori et al 23 showed SARC-F as a practical predictor of prognosis for cancer patients who were receiving palliative care. Trussardi Fayh et al 24 presented its association with a longer length of stay and hospital readmission after a cardiovascular event. Another important study was conducted by Bahat et al, 25 who showed the predicting capacity of SARC-F to define frailty.…”

Section: Discussionmentioning

confidence: 99%

Significance of Screening Frailty, Sarcopenia, and Malnutrition in Hospitalized Patients with COVID-19: A One-Year Follow-Up Study

Öztürk¹

2023

J Clin Pract Res

View full text Add to dashboard Cite

Objective: This study aimed to explore the effect of sarcopenia, malnutrition, and frailty screening tools on one-year mortality in hospitalized adult patients with coronavirus disease 2019 (COVID-19). Materials and Methods: Patients, 18 years of age, who were admitted to the COVID-19 clinic were enrolled in this prospective study. The clinical frailty scale (CFS) and SARC-F questionnaire were used for frailty and sarcopenia screening. Nutrition Risk Screening (NRS-2002) and Mini Nutritional Assessment-Short Form (MNA-SF) were performed to screen for malnutrition. The survival of all participants was investigated by using the Turkish national death registry. Multivariable logistic regression analyses were performed. Results: A total of 72 subjects were enrolled in this study. The rate of patients with sarcopenia risk, malnutrition risk (via MNA-SF), malnutrition risk (via NRS-2002), and living with frailty were 75%, 93.8%, 81.3%, and 50.0% in the deceased group, respectively. Conversely, the rates of patients with sarcopenia risk, malnutrition risk (via MNA-SF), malnutrition risk (via NRS-2002), and living with frailty were 23.2%, 71.4%, 60.7%, and 16.1% in the alive group, respectively. SARC-F score (OR 1.331, p=0.006), MNA-SF score (OR 1.695, p=0.002), NRS-2002 score (OR 1.580, p=0.024), and CFS (OR 1.639, p=0.009) score were independently associated with one-year mortality after adjusting for sex and age. Conclusion: MNA-SF, SARC-F, and CFS may be used for mortality risk estimation after discharge from the hospital who were admitted for acute disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Significance of Screening Frailty, Sarcopenia, and Malnutrition in Hospitalized Patients with COVID-19: A One-Year Follow-Up Study

Öztürk¹

2023

J Clin Pract Res

View full text Add to dashboard Cite

show abstract

“…Previous studies have documented the substantial impact of skeletal muscle abnormalities on the prognosis of cardio-cerebrovascular disease, malignancy and even the all-cause mortality in the general population [4][5][6][7]. At present, the role of muscle alterations on the development and outcomes of chronic liver diseases also becomes a major concern of the hepatologists [8,9].…”

Section: Introductionmentioning

confidence: 99%

Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China

Zeng

Shi

et al. 2023

Hepatol Int

View full text Add to dashboard Cite

Introduction: We aimed to determine the diagnostic criteria of myosteatosis in a Chinese populationand investigate the effect of skeletal muscle abnormalities on the outcomes of cirrhotic patients.Methods: Totally 911 volunteers were recruited to determine the diagnostic criteria and impact factors of myosteatosis, and 480 cirrhotic patients were enrolled to verify the value of muscle alterations for prognosis prediction and establishnew noninvasive prognostic strategies.Results: Multivariate analysis showed age, sex, weight, waist circumference and biceps circumference had remarkable in uence on the L3 skeletal muscle density (L3-SMD). Based on the cut-off of a mean−1.28×SD among adults aged 60 years, the diagnostic criteria for myosteatosis wasL3-SMD 38.93 Hu in malesand L3-SMD 32.82 Hu in females. Myosteatosis rather than sarcopenia has close correlation with portal hypertension. The concurrence of sarcopenia and myosteatosis not only is associated with poor liver function, but also evidently reduced the overall and liver transplantation-free survival of the cirrhotic patients (P<0.001). According to the stepwise Cox regression hazard model analysis, we established nomograms including TBil, albumin, history of HE, ascites grade, sarcopenia and myosteatosis for easily determining survival probabilities in cirrhotic patients. The AUC is 0.874 (95% CI, 0.800-0.949) for 6-month survival, 0.831 (95% CI, 0.764-0.898) for 1-year survival and 0.813 (95% CI, 0.756-0.871) for 2-year survival prediction, respectively.Conclusions: This study provides evidence of the signi cant correlation between skeletal muscle alterations andpoor outcomes of cirrhosis, and establishes valid and convenient nomograms incorporating musculoskeletal disorders for the prognostic prediction of liver cirrhosis. Further large-scale prospective studies are necessary to verify the value of the nomograms.

show abstract

Sarcopenia screening and clinical outcomes in surgical patients: A longitudinal study

Tarnowski,

Burgel,

Dariva

et al. 2024

Nut in Clin Prac

View full text Add to dashboard Cite

BackgroundThe SARC‐CalF was developed as a screening tool for sarcopenia, but little is still known about its validity in surgical patients. Thus, this study aimed to assess the prognostic value of SARC‐CalF in predicting clinical outcomes in patients admitted for any elective surgery in a hospital.MethodsCohort study with prospective data collection of surgical patients ≥18 years of age screened for sarcopenia within 48 h of admission using the SARC‐CalF (score ≥11 points classified patients at suggestive signs of sarcopenia). A standard questionnaire for sociodemographic and clinical data was filled and anthropometric data were measured. Clinical outcomes of interest comprised postoperative complications, length of postoperative hospital stay (LPHS), length of hospital stay (LOS), and in‐hospital death.ResultsAmong the 303 patients admitted for elective surgery across various specialties (58.2 ± 14.6 years; 53.8% men) included, 21.5% presented suggestive signs of sarcopenia (SARC‐CalF ≥11). LOS (16.0 [10.0–29.0] vs 13.5 [8.0–22.0] days; P < 0.05) and LPHS (6.0 [3.0–14.5] vs 5.0 [1.0–8.2] days; P < 0.05) were longer in patients with SARC‐CalF ≥11 compared with those without this condition. The frequency of severe postoperative complications (23.1% vs 8.8%; P < 0.05) and the incidence of death (12.3% vs 2.9%; P < 0.05) were higher in patients with SARC‐CalF ≥11. However, in the multivariate analyses, no association between SARC‐CalF ≥11 and clinical outcomes was found.ConclusionSigns of sarcopenia (SARC‐CalF ≥11) were present in >20% of patients who were hospitalized for any elective surgery, but it was not an independent predictor of extended hospital stay, complications, and death.

show abstract

SARC-F Is a Predictor of Longer LOS and Hospital Readmission in Hospitalized Patients after a Cardiovascular Event

Cited by 9 publications

References 36 publications

Significance of Screening Frailty, Sarcopenia, and Malnutrition in Hospitalized Patients with COVID-19: A One-Year Follow-Up Study

Significance of Screening Frailty, Sarcopenia, and Malnutrition in Hospitalized Patients with COVID-19: A One-Year Follow-Up Study

Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China

Sarcopenia screening and clinical outcomes in surgical patients: A longitudinal study

Contact Info

Product

Resources

About